|
Match
|
Document |
Document Title |
|
|
5316933 |
Recombinant natural killer cell activator
A recombinant natural killer cell activating factor is disclosed, preferably having a peptide of the following amino acid sequence in its molecule. The invention provides a cDNA coding for a...
|
|
|
5317087 |
Purification of the IL-2 receptor
Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromatography in conjunction with a monoclonal antibody directed to...
|
|
|
5314995 |
Therapeutic interleukin-2-antibody based fusion proteins
The present invention relates to antibody-based fusion proteins wherein a portion of an immunoglobulin molecule is linked to a biologically active ligand. In particular embodiments of the...
|
|
|
5312621 |
Method of treating fibrotic disorders
A novel method of treating fibrotic disorders in humans comprises the administration of a sufficient quantity of a composition containing a human alpha- or beta-interferon to raise the total...
|
|
|
5306627 |
Process for producing a human neutrophil chemotactic factor peptide and a recombinant expression vector for the said polypeptide
An expression vector in which a DNA encoding a human neutrophil chemotactic factor polypeptide is inserted, a transformant (a host cell transformed with the expression vector), and a process for...
|
|
|
5298603 |
GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
Expression of a gene coding for human granulocyte macrophage colony-stimulating factor (CSF) in bacteria results in CSF proteins which are biologically active. Modification of the natural or of a...
|
|
|
5292654 |
Mutant EPO receptor and uses therefor
A mutant erythropoietin receptor of mammalian origin which is hypersensitive to erythropoietin, DNA encoding the mutant erythropoietin receptor and uses therefor. An assay method for identifying...
|
|
|
5290917 |
Modified polypeptides of IL-1α
Novel polypeptides having a modified amino acid sequence of human interleukin 1α polypeptides in which a certain amino acid residue(s) in said amino acid sequence is(are) exchanged for other amino...
|
|
|
5288852 |
Human tumor necrosis factor polypeptides
A novel cloned DNA encoding a human tumor necrosis factor (TNF), a vector having said DNA inserted thereinto, a host transformed with said vector and a novel human TNF polypeptide, and processes...
|
|
|
5286847 |
Interleukin-1 muteins, their preparation and method of use to inhibit interleukin-1 activity
Disclosed are novel muteins of IL-1 compounds which can be used to regulate excess IL-1 produced in various diseases in humans and animals. The IL-1 muteins can be prepared by site-directed...
|
|
|
5278287 |
Human cytokine
A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound...
|
|
|
5273889 |
Gamma-iterferon-leukotoxin gene fusions and uses thereof
New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are...
|
|
|
5272082 |
Cytotoxic T-ALL cell lines and uses therefor
The invention provides cytotoxic T-ALL cell lines, and modified cytotoxic T-ALL cell lines which contain a heterologous DNA sequence. The DNA sequence may encode a product capable of stabilizing or...
|
|
|
5262309 |
Terminal modifications of tumor necrosis factor
This invention relates to a novel physiologically active polypeptide containing modified amino acids on both terminals at the amino-terminus and the carboxy-terminus in the amino acid sequence of...
|
|
|
5256769 |
Mutual separation of proteins
A protein of interest or a Met-protein, e.g. the N-Met analog of the protein of the interest can be efficiently separated from a mixture thereof by subjecting the mixture to a separation procedure...
|
|
|
5248769 |
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves first reducing the...
|
|
|
5247070 |
N-terminal muteins of tumor necrosis factor
A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its...
|
|
|
5238823 |
Interleukin-2-leukotoxin gene fusions and uses thereof
New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are...
|
|
|
5221620 |
Cloning and expression of transforming growth factor β2
cDNA clones coding for TGF-β2 which are used to construct expression vectors capable of directing the high-level expression of mature, biologically active TGF-β2, as well as precursor TGF-β2...
|
|
|
5218092 |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
A polypeptide or glycosylated polypeptide with at least one new carbohydrate chain produced by means of recombinant DNA technique, which has protease resistance and thermal stability and is...
|
|
|
5215895 |
DNA encoding a mammalian cytokine, interleukin-11
A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune...
|
|
|
5212087 |
ARS sequence which is efficacious in yarrowia lipolytica
The present invention relates to ars sequences which are efficacious in Yarrowia lipolytica, as well as to plasmids carrying these sequences. The strains of Y. lipolytica transformed with the said...
|
|
|
5212073 |
Process for producing human JE cytokine
A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound...
|
|
|
5210029 |
Method of producing interleukin-2
The present invention provides an improvement in a method for producing physiologically active proteins by cultivating Escherichia coli having an expression vector which contains a structural gene...
|
|
|
5206344 |
Interleukin-2 muteins and polymer conjugation thereof
Muteins of IL-2 in which one of the amino acids of the mature native sequence of IL-2 is replaced by a cysteine residue are prepared and conjugated through the replaced cysteine residue to a...
|
|
|
5182196 |
Expression systems for overproduction of desired proteins
Recombinant DNA molecules comprising DNA sequences derived from bacteriophage T4 that are useful in expressing desired polypeptides in unexpectedly high yields, hosts and expression systems...
|
|
|
5179199 |
Protein purification
A method of removing an organic solvent from a mixture that includes a compound having a polypeptide segment and the organic solvent, the method including the steps of contacting the mixture with...
|
|
|
5171675 |
Macrophage colony stimulating factor-γ
A macrophage colony stimulating factor, M-CSFγ, which is a primary translation product of an alternative mRNA splicing event and is a precursor to biologically active M-CSF. DNA sequences encoding...
|
|
|
5169765 |
Method for stimulating production of bone marrow cell growth factors using dithiocarbamates
A process is provided for obtaining one or more bone marrow cell growth factors having granulocyte/macrophage progenitor cell colony stimulating activity, said process comprising: (a) adding to the...
|
|
|
5166322 |
Cysteine added variants of interleukin-3 and chemical modifications thereof
Cysteine added variants ("CAVs") of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the...
|
|
|
5157106 |
N-terminal deletions of lymphotoxin, their preparation and use
Polypeptides which differ from lymphotoxin by the absence of amino acids at the N-terminal end of the lymphotoxin are described. The polypeptides can be prepared by gene manipulation and are...
|
|
|
5155211 |
Megakaryocyte stimulatory factor
A megakaryocyte stimulatory factor (MSF), purified to homogeneity, is an acidic protein (pI=5.1) with an Mr=15,000 which stimulates PF4-like protein synthesis in rat promegakaryoblast cells by as...
|
|
|
5139936 |
Use of the GAL1 yeast promoter
A DNA segment contains a GAL1 promoter of Saccharomyces cerevisae linked to a gene other than the galoctokinase gene, for directing the expression of the gene within a yeast cell. A GAL1 promoter...
|
|
|
5136024 |
Extraction of granulocyte macrophage colony stimulating factor from bacteria
A method of extracting granulocyte/macrophage colony stimulating factor (GM-CSF) from GM-SCF-expressing bacterial cells comprising treating a suspension of GM-CSF-containing bacterial cells with an...
|
|
|
5126250 |
Method for the reduction of heterogeneity of monoclonal antibodies
Novel methods for reducing the heterogeneity of secreted monoclonal antibodies are disclosed. The first method comprises incubating the heterogeneous antibodies at low pH for a length of time...
|
|
|
5116943 |
Oxidation-resistant muteins of Il-2 and other protein
A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine...
|
|
|
5112961 |
DNA encoding subunits of a high affinity GM-CSF receptor
Nucleic acids encoding the β chain of the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, as well as the β chain itself, are provided. The β chain may be expressed with...
|
|
|
5108910 |
DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
A DNA sequence encoding fusion protein is disclosed which comprises GM-CSF and IL-3. Such fusion proteins more biologically active than GM-CSF or IL-3 alone or GM-CSF and IL-3 combined.
|
|
|
5106733 |
Bovine granulocyte-macrophage colony stimulating factor
Cloning and expression of DNA segments encoding bovine GM-CSF, and processes for producing recombinant bovine GM-CSF as a product of recombinant cell culture, are disclosed.
|
|
|
5104651 |
Stabilized hydrophobic protein formulations of G-CSF
A stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein is disclosed. Also disclosed are associated means and methods for preparing such...
|
|
|
5094960 |
Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
A method of removing lipid soluble chemicals from a biological material containing the lipid soluble chemicals comprising subjecting the biological material containing the lipid soluble chemicals...
|
|
|
5082927 |
Selectively cytotoxic IL-4-PE40 fusion protein
The present invention provides a chimeric protein IL4-PE40 which selectively kills IL4 receptor bearing cells. A mutant form of the protein is also provided.
|
|
|
5082657 |
Leukoregulin, an antitumor lymphokine, and its therapeutic uses
Leukoregulin is identified, a biologically active lymphokine of molecular weight of about 120,000 to 140,000 with subunits of about 30,000 to 35,000, having the isoelectric focusing pH's of between...
|
|
|
5082783 |
Enhanced secretion of heterologous proteins by hosts using substituted promoters
Improved secretion of heterologous proteins by hosts such as yeast by using promoters of at most intermediate strength with heterologous DNA secretion signal sequences is disclosed. A promoter of...
|
|
|
5081228 |
Interleukin-1 receptors
Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including...
|
|
|
5081028 |
Preparation of transformed hosts which express binding factor related polypeptides
The invention concerns polypeptides related to human immunoglobulin E binding factors (IgE-Bfs), mRNa, DNAs and hybrid vectors coding for said polypeptides, hosts containing said hydrid vectors,...
|
|
|
5081021 |
DNA encoding HTNF variants exhibiting enhanced activity
Novel DNA's encoding variants of TNF which comprise substitutions and/or deletions in the n-terminal portion of the TNF polypeptide resulting in enhanced cytotoxic activity are taught.
|
|
|
5078996 |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be...
|
|
|
5073627 |
Fusion proteins comprising GM-CSF and IL-3
A fusion protein is disclosed which comprises GM-CSF and IL-3. Such fusion proteins more biologically active than GM-CSF or IL-3 alone or GM-CSF and IL-3 combined.
|
|
|
5071761 |
Hybrid interferons
Novel hybrid interferons are produced which are derived from lymphoblastoid interferons α-2 and α-3 belonging to the interferon αB and αD groups, respectively. The novel hybrid interferons...
|